BEN-MAIMON CAROLE 4

What Happened
Carole Ben‑Maimon, President, CEO and a director of Larimar Therapeutics (LRMR), was awarded a total of 700,700 restricted stock units (RSUs) on 2026-01-26. The filing shows two awards: 100,100 shares (acquired) and 600,600 shares reported as a derivative award, all at $0.00 (i.e., granted, not purchased). Per the filing, each RSU is a contingent right to receive one share of common stock upon settlement.

Key Details

• Transaction date: 2026-01-26; filing date: 2026-01-27 (timely).
• Awards: 100,100 RSUs (non-derivative) and 600,600 RSUs (derivative), total 700,700 RSUs; grant price reported $0.00.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes of note: F1 clarifies each RSU is a contingent right to one share on settlement. F2–F6 disclose certain shares are held in irrevocable trusts for family members for which Ms. Ben‑Maimon serves as trustee and she disclaims beneficial ownership except to the extent of any pecuniary interest.
• No sale or cash exercise occurred; this is an award/grant (transaction code A).

Context
RSUs are compensation awards that convert to actual shares only upon settlement (vesting or other conditions); they are not immediate cash purchases or sales and do not necessarily signal insider buying/selling intent. The derivative classification simply reflects a right to future shares. Retail investors should view this as an executive equity award rather than an open‑market purchase.